235 related articles for article (PubMed ID: 28457804)
1. The clinical pharmacology of non-sedating antihistamines.
Yanai K; Yoshikawa T; Yanai A; Nakamura T; Iida T; Leurs R; Tashiro M
Pharmacol Ther; 2017 Oct; 178():148-156. PubMed ID: 28457804
[TBL] [Abstract][Full Text] [Related]
2. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine.
Hiraoka K; Tashiro M; Grobosch T; Maurer M; Oda K; Toyohara J; Ishii K; Ishiwata K; Yanai K
Expert Opin Drug Saf; 2015 Feb; 14(2):199-206. PubMed ID: 25466429
[TBL] [Abstract][Full Text] [Related]
3. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin.
Tashiro M; Duan X; Kato M; Miyake M; Watanuki S; Ishikawa Y; Funaki Y; Iwata R; Itoh M; Yanai K
Br J Clin Pharmacol; 2008 Jun; 65(6):811-21. PubMed ID: 18410464
[TBL] [Abstract][Full Text] [Related]
4. Why are second-generation H1-antihistamines minimally sedating?
Hu Y; Sieck DE; Hsu WH
Eur J Pharmacol; 2015 Oct; 765():100-6. PubMed ID: 26291661
[TBL] [Abstract][Full Text] [Related]
5. Cerebral histamine H1 receptor binding potential measured with PET under a test dose of olopatadine, an antihistamine, is reduced after repeated administration of olopatadine.
Senda M; Kubo N; Adachi K; Ikari Y; Matsumoto K; Shimizu K; Tominaga H
J Nucl Med; 2009 Jun; 50(6):887-92. PubMed ID: 19443589
[TBL] [Abstract][Full Text] [Related]
6. [A potential of positron emission tomography in the drug development of non-sedative antihistamines].
Tashiro M; Yanai K
Nihon Yakurigaku Zasshi; 2003 Nov; 122 Suppl():78P-80P. PubMed ID: 14727529
[TBL] [Abstract][Full Text] [Related]
7. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.
Kawauchi H; Yanai K; Wang DY; Itahashi K; Okubo K
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626077
[TBL] [Abstract][Full Text] [Related]
8. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography.
Tashiro M; Sakurada Y; Iwabuchi K; Mochizuki H; Kato M; Aoki M; Funaki Y; Itoh M; Iwata R; Wong DF; Yanai K
J Clin Pharmacol; 2004 Aug; 44(8):890-900. PubMed ID: 15286093
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants responsible for sedative and non-sedative properties of histamine H₁-receptor antagonists.
Uesawa Y; Hishinuma S; Shoji M
J Pharmacol Sci; 2014; 124(2):160-8. PubMed ID: 24476926
[TBL] [Abstract][Full Text] [Related]
10. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies.
Yanai K; Tashiro M
Pharmacol Ther; 2007 Jan; 113(1):1-15. PubMed ID: 16890992
[TBL] [Abstract][Full Text] [Related]
11. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.
Farré M; Pérez-Mañá C; Papaseit E; Menoyo E; Pérez M; Martin S; Bullich S; Rojas S; Herance JR; Trampal C; Labeaga L; Valiente R
Br J Clin Pharmacol; 2014 Nov; 78(5):970-80. PubMed ID: 24833043
[TBL] [Abstract][Full Text] [Related]
12. Dose dependency of brain histamine H(1) receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C]doxepin.
Tashiro M; Kato M; Miyake M; Watanuki S; Funaki Y; Ishikawa Y; Iwata R; Yanai K
Hum Psychopharmacol; 2009 Oct; 24(7):540-8. PubMed ID: 19697300
[TBL] [Abstract][Full Text] [Related]
13. Brain histamine H1 receptor occupancy of loratadine measured by positron emission topography: comparison of H1 receptor occupancy and proportional impairment ratio.
Kubo N; Senda M; Ohsumi Y; Sakamoto S; Matsumoto K; Tashiro M; Okamura N; Yanai K
Hum Psychopharmacol; 2011 Mar; 26(2):133-9. PubMed ID: 21433074
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography evaluation of sedative properties of antihistamines.
Yanai K; Zhang D; Tashiro M; Yoshikawa T; Naganuma F; Harada R; Nakamura T; Shibuya K; Okamura N
Expert Opin Drug Saf; 2011 Jul; 10(4):613-22. PubMed ID: 21521134
[TBL] [Abstract][Full Text] [Related]
15. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving.
Jáuregui I; Ramaekers JG; Yanai K; Farré M; Redondo E; Valiente R; Labeaga L
Expert Opin Drug Saf; 2016 Jan; 15(1):89-98. PubMed ID: 26571227
[TBL] [Abstract][Full Text] [Related]
16. [Functional neuropharmacology in the human brain using positron emission tomography: PET imaging of impaired cognitive performance induced by sedative antihistamines].
Yanai K; Okamura N; Itoh M; Watanabe T
Nihon Yakurigaku Zasshi; 1998 Oct; 112 Suppl 1():48P-52P. PubMed ID: 10190133
[TBL] [Abstract][Full Text] [Related]
17. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice.
Yanai K; Okamura N; Tagawa M; Itoh M; Watanabe T
Clin Exp Allergy; 1999 Jul; 29 Suppl 3():29-36; discussion 37-8. PubMed ID: 10444209
[TBL] [Abstract][Full Text] [Related]
18. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis.
Bender BG; Berning S; Dudden R; Milgrom H; Tran ZV
J Allergy Clin Immunol; 2003 Apr; 111(4):770-6. PubMed ID: 12704356
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Non-brain Penetrating H
Yanai K; Yoshikawa T; Church MK
Curr Top Behav Neurosci; 2022; 59():193-214. PubMed ID: 34622396
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.
Zuberbier T
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):9-18. PubMed ID: 21797930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
